Clinical Trials
105 trialsCombination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
TroFuse-020
Merck Sharp & Dohme LLC
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
TROPION-Lung12
AstraZeneca
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
Children's Oncology Group
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
AstraZeneca
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
Hoffmann-La Roche
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
Sichuan Baili Pharmaceutical Co., Ltd.
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
Sichuan Baili Pharmaceutical Co., Ltd.
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Children's Oncology Group
innovaTV 301
Seagen Inc.
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Gilead Sciences
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
CheckMate 816
Bristol-Myers Squibb
COMET
Intergroupe Francophone de Cancerologie Thoracique
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
Sun Yat-sen University
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
PRECIOUS
Japan Breast Cancer Research Group
ALPHABET
Spanish Breast Cancer Research Group
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Qilu Pharmaceutical Co., Ltd.
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
National Cancer Institute (NCI)
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Shanghai Yizhong Pharmaceutical Co., Ltd.
IPSOS
Hoffmann-La Roche
TROPiCS-02
Gilead Sciences
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Qilu Pharmaceutical Co., Ltd.
ARCTIC
AstraZeneca
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
Shanghai Chest Hospital
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
Sun Yat-sen University
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
RemeGen Co., Ltd.
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
Sun Yat-sen University
TULIP
Byondis B.V.
DP303c in Patients With HER2-positive Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
ATTAIN
Nektar Therapeutics
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
Agenus Inc.
ASCENT
Gilead Sciences
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Children's Oncology Group
KEYNOTE-119
Merck Sharp & Dohme LLC
EVIDENCE
Betta Pharmaceuticals Co., Ltd.
Toco-Pulm
Vejle Hospital